{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:46:34Z","timestamp":1792590394798,"version":"4.5.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the safety and efficacy of cabergoline to control hypersomatotropism (HST) and diabetes mellitus (DM) in cats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective cohort study. Twenty-three cats with HST and concurrent DM were enrolled. Cats received a dose of 10\u2009\u03bcg\/kg cabergoline q48h PO for 6 months. Serum insulin-like growth factor 1 (IGF-1) and fructosamine concentrations, insulin dose and Insulin Resistance Index (IRI) were measured at the time of diagnosis of HST and at the start of cabergoline treatment (t0), and 3 months (t1) and 6 months (t2) during cabergoline treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A decrease and normalization of serum IGF-1 concentration was observed in 35% and 26% of cats, respectively. Median IGF-1 (t0: 1350\u2009ng\/ml [range 832\u20131501]; t1: 1284\u2009ng\/ml [range 365\u20131501]; t2: 1240\u2009ng\/ml [range 263\u20131501];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.016) decreased significantly. Twelve cats underwent diagnostic imaging of the pituitary area. The median pituitary height at t0 of cats that experienced an IGF-1 reduction (n\u2009=\u20095\/12) was significantly lower compared with those that did not experience an IGF-1 reduction (n\u2009=\u20097\/12) (3.2\u2009mm [range 3.1\u20133.7] vs 6\u2009mm [range 3.5\u20139.5];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.011). Median fructosamine (t0: 628\u2009\u00b5mol\/l [range 400\u2013963]; t1: 404\u2009\u00b5mol\/l [range 249\u2013780]; t2: 400\u2009\u00b5mol\/l [range 260\u2013815];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001), insulin dose (t0: 1.3\u2009IU\/kg [range 0.5\u20134.6]; t0: 0.5 IU\/kg [range 0\u20132.3]; t2: 0.4\u2009IU\/kg [range 0\u20132.1];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001) and IRI (t0: 800\u2009\u00b5molIU\/kgl [range 257\u20132700]; t1: 300\u2009\u00b5molIU\/kgl [range 0\u20131498]; t2: 250\u2009\u00b5molIU\/kgl [range 0\u20131498];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001) decreased significantly during cabergoline treatment. Eight cats achieved diabetic remission between months 1 and 6 of cabergoline treatment (median time to achieve remission: 3 months [range 1\u20136]). Three cats experienced asymptomatic hypoglycemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>Cabergoline was effective in normalizing IGF-1 concentration in 26% of cats. Cabergoline improved diabetes control and was associated with remission of DM in 35% of cases. Cabergoline could be a treatment option for cats with HST and DM, especially in those cases with a relatively small pituitary tumor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x221074924","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T09:39:34Z","timestamp":1644313174000},"page":"1238-1244","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2271-2741","authenticated-orcid":false,"given":"Diego D","family":"Miceli","sequence":"first","affiliation":[{"name":"Hospital School of Veterinary Medicine, University of Buenos Aires, Faculty of Veterinary Sciences, Buenos Aires, Argentina"},{"name":"Laboratory of Molecular Endocrinology and Signal Transduction, Institute of Experimental Biology and Medicine \u2013 CONICET, Buenos Aires, Argentina"},{"name":"Veterinary Science Center, Maimonides University, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge D","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Hospital School of Veterinary Medicine, University of Buenos Aires, Faculty of Veterinary Sciences, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A","family":"Pompili","sequence":"additional","affiliation":[{"name":"Hospital School of Veterinary Medicine, University of Buenos Aires, Faculty of Veterinary Sciences, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-0318","authenticated-orcid":false,"given":"Juan P","family":"Rey Amunategui","sequence":"additional","affiliation":[{"name":"Veterinary Science Center, Maimonides University, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ferraris","sequence":"additional","affiliation":[{"name":"Veterinary Science Center, Maimonides University, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar P","family":"Pignataro","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Endocrinology and Signal Transduction, Institute of Experimental Biology and Medicine \u2013 CONICET, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirtha","family":"Guitelman","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Hospital Carlos G Durand, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-6374(03)00076-5"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00226"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127794"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X16664390"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0071-6"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X20933213"},{"key":"e_1_3_2_10_2","article-title":"Diabetes mellitus remission in three cats with hypersomatotropism after cabergoline treatment.","volume":"7","author":"Miceli DD","year":"2021","unstructured":"Miceli DD, Vidal PN, Pompili GA, et al. Diabetes mellitus remission in three cats with hypersomatotropism after cabergoline treatment. JFMS Open Rep 2021; 7. DOI: 10.1177\/20551169211018991.","journal-title":"JFMS Open Rep"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.17533\/udea.rccp.v30n4a07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16047"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15212"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.14662"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.2005.00006.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X17723774"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2012.12.004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2004.01.002"},{"key":"e_1_3_2_19_2","first-page":"757","article-title":"Evaluation of a long-acting somatostatin receptor ligand for the treatment of feline acromegaly. 2012 ACVIM Forum Research Abstracts Program.","volume":"26","author":"Timian J","year":"2012","unstructured":"Timian J, Lunn KF. Evaluation of a long-acting somatostatin receptor ligand for the treatment of feline acromegaly. 2012 ACVIM Forum Research Abstracts Program. J Vet Int Med 2012; 26: 757.","journal-title":"J Vet Int Med"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.2002.tb12469.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0383-y"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00514-0"},{"key":"e_1_3_2_23_2","article-title":"Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment.","volume":"13","author":"Miceli DD","year":"2021","unstructured":"Miceli DD, Zelaray\u00e1n GS, Garc\u00eda JD, et al. Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment. JFMS Open Rep 2021; 13. DOI: 10.1177\/20551169211029896.","journal-title":"JFMS Open Rep"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12608"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2008.0242.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16080"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.12.029"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90057-4"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000054344"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0017"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.04.026"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14183"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0277-9"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12204"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2007.08.009"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X221074924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X221074924","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X221074924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:20:24Z","timestamp":1792588824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X221074924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/1098612X221074924"],"URL":"https:\/\/doi.org\/10.1177\/1098612x221074924","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}